Tuesday, June 16, 2020, 5:00 PM – 6:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA Complimentary CNE (NCPD) Live Webinar Series

Locally Advanced Non-Small Cell Lung Cancer

Register Today for This CNE (NCPD) Virtual Event — 1.5 Credit Hours Available

Live Webinar

Join Us on Tuesday, June 16
5:00 PM – 6:30 PM ET

Complimentary Registration
A link to the event will be provided after registration.

 
 
Faculty

Faculty to be announced

Moderator

Neil Love, MD
Research To Practice
Miami, Florida


Topics for Discussion

  • Module 1: Current Role of Durvalumab Consolidation for Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Module 2: Optimal Timing of Durvalumab Following the Completion of CRT; Impact of Radiation-induced Toxicities on its Use
  • Module 3: Spectrum, Frequency and Management of Immune-Mediated Adverse Events (AEs) with Anti-PD-1/PD-L1 Antibodies; Contraindications to Their Use
A detailed agenda will be made available in the coming weeks.

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Appreciate the benefits, risks and long-term outcomes associated with current local and/or systemic treatment modalities in the management of resectable or unresectable locally advanced non-small cell lung cancer (NSCLC), and consider this information when counseling patients.
  • Evaluate available research data documenting the efficacy and safety of sequential anti-PD-L1 antibody therapy for patients with unresectable locally advanced NSCLC.
  • Review the recent FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
  • Develop an understanding of which clinical and biologic factors (eg, chemoradiation therapy-related toxicities, PD-L1 status, EGFR or ALK status) are relevant in the decision to use anti-PD-L1 antibody consolidation therapy for unresectable Stage III NSCLC to better counsel patients about current therapeutic recommendations.
  • Recognize immune-related adverse events and other common side effects of anti-PD-L1 antibody consolidation therapy in patients with Stage III NSCLC, and offer supportive strategies to minimize and/or manage these toxicities.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with locally advanced NSCLC to optimize clinical and quality-of-life outcomes.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.